Oncogenic epidermal growth factor receptor (EGFR) signaling plays an important role in
regulating global metabolic pathways, including aerobic glycolysis, the pentose phosphate …

Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …

Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …

A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …

Introduction Tumor microenvironment critically affects cancer progression. This study aimed
to identify differences in microenvironments of lung adenocarcinomas with epidermal growth …

Background Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of …

Background There is little information on the clinical outcome of patients with small-cell lung
cancer (SCLC) treated with third-line chemotherapy. The purpose of this study was to clarify …

Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an
immune response to cancer. However, a disruption of the immune checkpoint function by …

Simple Summary Gut microbiota is a key regulators of the efficacy of immune checkpoint
inhibitor (ICIs). Thus, manipulating microbiota may enhance cancer treatment outcomes. …

Introduction The impact of immune checkpoint blockade on immunity in cancer patients is
not completely elucidated due to the complexity of the immune network. Recent studies have …